Ocular Therapeutix has announced that its OTX-CSI (cyclosporine intracanalicular insert) failed to meet its primary endpoint in the Phase II dry eye disease (DED) treatment trial.

OTX-CSI, a long-acting, preservative-free cyclosporine intracanalicular insert, resides in the canaliculus and occludes the punctum.

The randomised, double-masked, multi-centre and vehicle-controlled Phase II clinical trial was conducted at 15 locations across the US.

The durability, tolerability, safety and efficacy of OTX-CSI’s two different formulations were evaluated in the trial by measuring the symptoms and signs of DED in 140 people who received treatment in both eyes over nearly 16 weeks.

OTX-CSI was given to 147 DED patients as part of the clinical trial, which was carried out by evaluating four groups.

The groups included OTX-CSI for a shorter duration (two to three months formulation-F1, n=42) and longer duration (three to four months formulation-F2a, n=40) as well as vehicle insert for a very short duration (one week formulation-F3, n=22) and longer duration (three to four months formulation-F2b, n=43).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the Phase II trial’s top-line data, OTX-CSI failed to meet the primary endpoint of increased tear production at 12 weeks, as measured by the Schirmer’s Test, compared to the vehicle-treated group.

The company noted that, generally, the OTX-CSI insert in both the formulations was observed to have a favourable safety profile and was tolerated well.

Ocular Therapeutix president and CEO Antony Mattessich said: “While we are disappointed by these results, demonstrating clinical benefit in patients with DED remains a significant unmet need and we will continue to review the data for additional information that may inform future development of this programme.

“We remain confident in the potential of our hydrogel-based formulation technology and its ability to deliver innovative ophthalmology therapies.

“We look forward to our anticipated Phase II top-line readout for OTX-DED for the short-term treatment of signs and symptoms of DED.”